MDXH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MDxHealth SA is not a strong buy right now for a beginner long-term investor, even with $50,000-$100,000 available. The pre-market move is positive, but the broader setup is still damaged by a major business reset, sharp analyst downgrades/price-target cuts, and no recent news flow to confirm a durable recovery. For an impatient investor who does not want to wait for a better entry, the stock is still too uncertain to call a clear buy today. Best current stance: hold and wait for evidence that the core prostate cancer business can offset the Resolve exit and that fundamentals stabilize.
Technically, MDXH is short-term oversold, with RSI_6 at 7.295, which can support a rebound attempt. MACD histogram is slightly positive and expanding, suggesting early momentum improvement. However, the moving averages remain bearish (SMA_200 > SMA_20 > SMA_5), which means the primary trend is still down. Price is also below the pivot at 0.702, with nearby support at 0.562 and resistance at 0.842. The pre-market price of 0.649 is above the key lower support but still inside a weak trend structure. In short: short-term bounce potential exists, but the trend remains bearish and not strong enough for an aggressive long-term buy.
["Pre-market price is up 8.17%, showing immediate buying interest.", "RSI is deeply oversold, which can support a short-term rebound.", "MACD histogram is positive and expanding, indicating improving momentum.", "Lake Street and TD Cowen still keep Buy ratings despite reduced price targets, implying some analysts still see long-term upside in the core prostate cancer business.", "Proprietary pattern statistics suggest a possible modest near-term bounce."]
["William Blair downgraded the stock to Market Perform after a weak Q1 and lower guidance.", "The company cut full-year revenue guidance by nearly 20% at the midpoint.", "MDxHealth is exiting the Resolve UTI business and closing the Texas lab, which is a major strategic setback.", "Novitas/Medicare recoupment issues around about $10M-$10.4M in prior Resolve payments create operational and reimbursement uncertainty.", "Recent news flow is absent, so there is no fresh catalyst confirming recovery.", "Hedge funds and insiders are neutral, showing no meaningful accumulation signal.", "Price targets were cut materially by multiple brokers, reflecting reduced confidence near term."]
Latest quarter: Q1 2026. The quarter was weak, with revenue coming in below expectations and pro forma sales about 9% below consensus. Management also cut 2026 guidance by just under 20% at the midpoint after deciding to exit the Resolve UTI business. That means growth trends are currently under pressure rather than accelerating. The core prostate cancer business still has support from some analysts, but the latest quarter does not yet show clear strength in the overall company trajectory.
Recent analyst action is negative overall. William Blair downgraded MDXH to Market Perform from Outperform. Lake Street, TD Cowen, and BTIG all kept Buy ratings but sharply reduced price targets, signaling caution despite continued long-term optimism in the core business. Wall Street’s pros generally still like the core prostate cancer franchise, but the cons are now dominant: weak Q1 results, guidance cuts, and reimbursement/legal uncertainty around Resolve. The overall analyst view is therefore mixed-to-bearish in the near term, with optimism only on a longer-term turnaround if execution improves.
